Where options run out, BRIA-ABC bets on survival in metastatic breast cancer

Metastatic breast cancer trial activity remains high, but GlobalData analysis shows development is still concentrated in Phase I and II studies. Metastatic breast cancer trial activity remains high, but GlobalData analysis shows development is still concentrated in Phase I and II studies. With BRIA-ABC the only late-stage cell therapy trial actively recruiting, the key question is whether Bria-IMT can turn early promise into a survival benefit. Credit: Parilov / Shutterstock.com Unlock FREE Access to Premium Content ​Discover exclusive forecasts, analyst insights, and in-depth clinical trials industry analysis across drug development, clinical research, and trial innovation. With a free Clinical Trials…

Source: Clinical Trials Arena